The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of panitumumab (P) plus mytomicin C (M), 5-fluorouracil (5-FU), and radiation (RT) in patients with squamous cell carcinoma of the anal canal (SCAC): Safety and efficacy profile—VITAL study, GEMCAD 09-02 clinical trial.
Jaime Feliu
No relevant relationships to disclose
Rocio Garcia-Carbonero
No relevant relationships to disclose
Jaume Capdevila
No relevant relationships to disclose
Inmaculada Guasch
No relevant relationships to disclose
Vicente Alonso
No relevant relationships to disclose
Carlos Lopez
No relevant relationships to disclose
Pilar Garcia-Alfonso
No relevant relationships to disclose
Carmen Castañon
No relevant relationships to disclose
Laura Cerezo
No relevant relationships to disclose
Isabel Sevilla
No relevant relationships to disclose
Carles Conill
No relevant relationships to disclose
Begona Quintana-Angel
No relevant relationships to disclose
Maria Elena Sanchez
No relevant relationships to disclose
Jose Lopez-Torrcilla
No relevant relationships to disclose
Ismael Ghanem
No relevant relationships to disclose
Juan Maurel
No relevant relationships to disclose